AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Permanent stock page ↗Health Care · Russell 2000
Next earnings: Thu 12 Nov 2026 · estimated
What 7 analyst firms say about ANTERIS TECHNOLOGIES GLOBAL CORP: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 8 analyst/firm records · 7 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
Recent analyst activity · last 90 days
Our tracked history has 4 reports on AVR from 3 analyst firms in the last 90 days (7 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it and 1 left it unchanged.
Ratings, latest available report against the previous one: 0 upgrades and 1 downgrade.
Latest observed target change: Barclays lowered its target from $18.00 (set 15 May 2026) to $10.00 on 7 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Christopher Pasquale | Hold | 7 Oct 2026 | 10.00 USD |
| Barclays | Matt Miksic | Hold | 7 Oct 2026 | — |
| Cantor Fitzgerald | Gabie Ingoglia | Buy | 14 Oct 2026 | 15.00 USD |
| Lake Street Capital Markets | Frank Takkinen | Buy | 23 Jan 2026 | 15.00 USD |
| TD Cowen | Joshua T Jennings | Buy | 13 May 2026 | 15.00 USD |
| Weiss Ratings | Unnamed analyst | — | 26 Aug 2026 | — |
| Wells Fargo | Larry Biegelsen | Buy | 11 Mar 2026 | 16.00 USD |
| Data feed RESEARCH | Research Team | Hold | 27 May 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:12 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.